Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors-Reference-Cited by-同舟云学术

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors

Published:2020-05-31 Issue:2 Volume:18 Page:322-326
ISSN:1738-1088
Container-title:Clinical Psychopharmacology and Neuroscience
language:en
Short-container-title:Clin Psychopharmacol Neurosci

Author:

Caroff Stanley N.¹^ORCID

Affiliation:

1. Department of Psychiatry, Corporal Michael J. Crescenz VA Medical Center and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Publisher

Korean College of Neuropsychopharmacology

Subject

Pharmacology (medical),Behavioral Neuroscience,Psychiatry and Mental health

Link

http://pdf.medrang.co.kr/CPN2/2020/018/cpn018-02-17.pdf

Reference24 articles.

1. Therapeutic Approaches to Tardive Dyskinesia

2. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

3. Neuroleptic Malignant Syndrome

4. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome

5. Neuroleptic malignant syndrome

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease;British Journal of Clinical Pharmacology;2022-12-28

2. Valbenazine, Fluphenazine, and Possible Neuroleptic Malignant Syndrome in a 58-Year-Old Woman;Journal of Clinical Psychopharmacology;2022-06-02

3. Neuroleptic Malignant Syndrome;Movement Disorder Emergencies;2021-10-03

4. Effect of Varenicline on Tardive Dyskinesia: A Pilot Study;Clinical Psychopharmacology and Neuroscience;2021-05-31

5. Drug-induced Hyperthermic Syndromes in Psychiatry;Clinical Psychopharmacology and Neuroscience;2021-02-28